

Special Issue

Targeted Therapy for Acute Myeloid Leukemia

Message from the Guest Editor

Acute myeloid leukemia (AML) is the most frequent acute leukemia and is genetically heterogeneous, as underlined by World Health Organization, National Comprehensive Network and European LeukemiaNet, among others. In AML, mutations, gene fusions, and chromosome deletions are frequent, but the number of co-mutations ranks lowest (average 13 mutations, only 5 of them recurrent) among adult cancers and constitute an actionable target in clinical medicine. This Special Issue aims to assemble a number of papers (original as well as reviews) that deal with targeted therapy for AML, both in the research and daily practice settings, with the aim to communicate and disseminate new avenues in this field.

Guest Editor

Dr. Fernando Ramos

Clinical Hematology, Hospital Universitario de León, 24071 León, Spain

Deadline for manuscript submissions

closed (28 February 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/115296

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)